Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
Status:
Completed
Trial end date:
2018-09-12
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well carfilzomib works in treating patients with
chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a
donor bone marrow or blood cell transplant, usually occurring more than three months after
transplant, in which donor cells damage the host tissue. Carfilzomib may be an effective
treatment for chronic graft-versus-host disease.